Cite
MLA Citation
Xi-Chun Hu et al.. “Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial.” Lancet oncology, vol. 16, no. 4, n.d., pp. 436–446. http://access.bl.uk/ark:/81055/vdc_100026005445.0x00003d